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PHN who have insufﬁcient pain relief with standard analgesics
and do not tolerate or are contraindicated to tricyclic antide-
pressants. The model structure allowed for differences in costs,
utilities and transition probabilities between the initial 30-day
run-in period and maintenance therapy and also took account of
other medications that are added in alongside gabapentin/lido-
caine plaster and those received by patients discontinuing
gabapentin/lidocaine plaster. Most transition probabilities were
based on clinical trials identiﬁed through a systematic literature
review. Missing data, including resource utilization, were
obtained from a Delphi panel and cost data from ofﬁcial price
lists and tariffs. Utilities derived from a published study using
the Health Utilities Index were adjusted for age and were sup-
plemented and validated by the Delphi panel. RESULTS: The
total cost for lidocaine plaster was £958 per patient, compared
with £789 for gabapentin, although lidocaine plaster generated
0.292 quality-adjusted life-years (QALYs), compared with 0.248
for gabapentin. Lidocaine plaster therefore cost £3767 ($7370;
95% conﬁdence interval: dominant, £13,415) per QALY gained
relative to gabapentin. Probabilistic sensitivity analysis demon-
strated that we can be 98.7% conﬁdent that lidocaine plaster is
cost-effective relative to gabapentin at a £20,000/QALY thresh-
old and 65% conﬁdent at a £5000/QALY threshold. Scenario
analyses and extensive one-way sensitivity analyses on all para-
meters including the time horizon conﬁrmed the robustness of
the results. CONCLUSION: The lidocaine 5% plaster is a highly
cost-effective treatment for PHN in Scotland.
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OBJECTIVES: QuantiFERON-TB Gold assay (QFT-G) is a
recently approved blood test for detection of tuberculosis (TB)
infection. The advantages of tuberculin skin test (TST) are;
improved speciﬁcity, unaffected by prior BCG vaccination, and
single patient visit. The aim of this study was to examine the cost
effectiveness of using QFT-G as a screening test followed by the
standard treatment of TB infected patients after exposure in close
contacts in Japan. METHODS: We used a Markov model to
compare the cost and effectiveness of QFT-G alone, TST alone,
and TST followed by QFT-G using a hypothetical adult cohort
(20 years old) of close contact patients with sputum-smear-
positive TB patients. Main outcome measure was incremental
cost per Quality adjusted life year (QALY) gained during life-
time. In the model, costs and effectiveness of each screening test,
further chest X-ray examination, prophylaxis after identifying as
infected patients, and treatment for overt tuberculosis patients
who is not identiﬁed by screening or suffer from the disease even
after prophylaxis were considered and estimated with published
literatures. Both deterministic one-way and probabilistic sensi-
tivity analysis were performed. RESULTS: TST alone was the
most expensive and the least effective alternative. The mean
QALYs for QFT-G only strategy was slightly higher than that for
TST followed by QFT-G strategy (27.0565 vs. 27.0564). Total
costs from the societal perspective were higher on average for
the TST followed by QFT-G strategy ($120.9) than the QFT-G
alone strategy ($112.9). The incremental cost effectiveness ratio
for QFT-G alone strategy dominated. The results were robust in
deterministic one-way sensitivity analysis while the acceptability
curve showed that the QFT-G alone strategy has 99.6% chance
of being cost effective at $50,000/QALY gained threshold. CON-
CLUSION: QFT-G alone strategy is the least expensive and the
most effective in screening the TB infection after exposure in
close contacts in Japan.
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OBJECTIVES: The purpose of this study was to estimate the
total and incremental costs associated with antibiotic treatments
for community acquired pneumonia (CAP). METHODS:
Persons over age 18 were identiﬁed in the Marketscan databases
July-December 2004. We identiﬁed CAP episodes for patients
with claims for ICD9 codes 481.XX–486.XX, plus the most fre-
quent antibiotics prescribed as initial treatment for an episode.
Logistic regression estimated a propensity score for each patient;
which was the predicted probability of using telithromycin.
Patients were then matched according to this probability. Then
exponential conditional means models (ECM) were speciﬁed,
controlling for variables that were still signiﬁcantly different
after the propensity score matching. These models allowed the
incremental costs to be estimated for treatment of telithromycin
relative to other antibiotics. RESULTS: The most common ini-
tial antibiotic treatments compared to telithromycin for CAP 
(n = 187 CAP episodes) were amoxicillin, azithromycin, clar-
ithromycin, levoﬂoxacin, moxiﬂoxacin, and a group of all other
antibiotics. The mean length of a CAP episode was from 11.5 to
16.5 days. Mean total expenditures among the episodes was
$897, with a range of $530 to $1175. Multivariate ECM models
were ﬁtted and showed signiﬁcant incremental cost reductions
per episode associated with telithromycin relative to: amoxicillin
(−$283, p = 0.002), azithromycin (−$686, p < 0.001), lev-
oﬂoxacin (−$411, p < 0.001), and moxiﬂoxacin (−$484, p <
0.001). The difference between telithromycin and clarithromycin
(−$52) was not signiﬁcant. CONCLUSION: The results of this
study show that the costs differed among episodes of CAP by the
initiating antibiotic. Use of propensity score matching and ECM
regression controlled for intra-episode differences, so the incre-
mental costs differences may be attributed to factors such as
length of episode. The costs of CAP can be substantial and it is
important to note that the initiating antibiotic may affect those
costs.
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OBJECTIVES: With increasing longevity among the elderly, it is
important to better understand the impact of chronic disease on
general health status. The objective of this study was to quan-
tify the health status burden of COPD for a nationally repre-
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sentative sample of Medicare beneﬁciaries. METHODS: This
study used data from the 2003 Medicare Current Beneﬁciary
Survey (MCBS), a continuous national sample of approximately
12,000 persons. Study patients were 65+ years old, eligible for
Medicare Parts A and B, and community residents. The COPD
cohort comprised patients with 1+ medical claim(s) with a
COPD diagnosis (ICD-9-CM codes: 491.xx, 492.x, 496). The
comparison cohort included non-COPD patients, with at least
one medical claim, matched 1:1 based on age, sex, race, and edu-
cation level. The study measures included self-rated general
health status, self-reported medical conditions, impairment in
activities of daily living (ADLs) and instrumental activities of
daily living (IADLs). RESULTS: A total of 1219 patients were
identiﬁed for the COPD cohort, all of whom were matched to
comparison cohort patients (mean age ± SD: 76 ± 7; 50%
female). COPD patients reported poorer general health (43%
reported “fair” or “poor” health versus 22% among controls; P
< 0.001) and more chronic medical conditions (mean of 4.2
versus 3.2 for controls; P < 0.001). COPD patients were also sig-
niﬁcantly (P < 0.001) more likely to report difﬁculties in per-
forming one or more ADLs (46% versus 28%) or IADLs (42%
versus 26%). For the COPD cohort, the most common ADL lim-
itations were difﬁculty walking (42%) and transferring from a
bed or chair (20%), while the most common IADL limitations
were difﬁculty doing heavy housework (42%) and shopping
(17%). CONCLUSION: In this community-residing Medicare
population, COPD patients reported poorer health and had
greater impairment in functioning than those without COPD.
These results have implications for improving COPD manage-
ment in the Medicare population.
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OBJECTIVES: Economic beneﬁts of early initiation of inhaled
corticosteroids (ICS) treatment in patients diagnosed with
Chronic Obstructive Pulmonary Disease (COPD) were assessed
using a large managed care claims database. METHODS: Early
initiation was deﬁned as beginning ICS within three months of
initiation of regular bronchodilators and was compared with
patients who initiated ICS therapy thereafter. To avoid biases due
to the treatment selection, a propensity-score-matching tech-
nique was used. Exacerbation risks and other resource utiliza-
tion per person-year were compared between the two groups. A
two-part model with multivariate logistic and generalized linear
model (GLM) regression was used to estimate differences in
medical, pharmacy, and total service costs. RESULTS: A total of
7712 matched COPD patients with comparable background
characteristics were identiﬁed. Early initiation of ICS was asso-
ciated with lower exacerbation risks and resource utilization.
Patients who started ICS within three months had more ICS pre-
scriptions (3.7 vs. 2.4 prescriptions per year) and higher phar-
macy costs ($4077 vs. $3868: mean difference +$209, p < 0.05).
However, because of lower medical services use, early initiation
of ICS could save medical costs ($13,837 vs. $14,925: mean dif-
ference −$1.089; p < 0.05) and total costs ($17,994 vs. $18,883:
mean difference −$889; p < 0.05). The same trends were
observed for services directly attributable to COPD conditions.
CONCLUSION: Initiating ICS earlier than the current clinical
guideline recommendation may be beneﬁcial to avoid exacerba-
tions and reduce treatment costs.
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OBJECTIVES: Gastrointestinal Stromal Tumours (GIST) are
rare cancers that generate high expenditures in the Mexican
Health System. The purpose of the study was to model the eco-
nomic and health consequences of second-line treatments (pre-
vious imatinib 400 mg/day failure) in adult patients with GIST
in advanced stages within the Social Security Mexican Institute.
METHODS: A cost–effectiveness analysis was developed using
a Markov modeling approach. The model simulates costs and
effectiveness outcomes in a ﬁve-year period. The model aimed 
to compare sunitinib 50 mg/day, imatinib 800 mg/day and local
best supportive care (BSC) as second-line treatments. Transition
probabilities of the Markov model were obtained according to
clinical trials previously published in the literature. Effectiveness
measures were the number of progression-free-months (PFM)
and life-years gained (LYG). The analysis was conducted from
the health care payer’s perspective (only direct medical costs were
used). Resource use and costs data was obtained from hospital
records at Hospital de Oncología CMN “Siglo XXI” in Mexico
City (n = 12). Both costs and health outcomes were discounted
using a 3% annual rate. Probabilistic sensitivity analysis was per-
formed and acceptability curves were constructed. RESULTS:
Second line treatment with imatinib showed the highest expected
costs (US$37,197.8 ± 1368.8) followed by sunitinib
(US$16,641.0 ± 368.6) and BSC (US$1900.7 ± 404.2). On the
other hand, the best clinical outcomes were obtained by suni-
tinib in both PFM and LYG (5.64 months, 1.4 years) followed
by imatinib (5.28 months, 1.3 years) and BSC (2.52 months, 1.1
years). Imatinib option resulted dominated by sunitinib and the
ICER between sunitinib and BSC was of US$49,134.3 per LYG.
Results were robust to Monte Carlo second order sensitivity
analysis and acceptability curves showed the same results. CON-
CLUSION: In Mexico, sunitinib second-line treatment was the
most cost—effective alternative compared to imatinib. These
results should be taken into account by Mexican decision makers
in the management of patients with GIST.
CN2
PHARMACOECONOMIC ANALYSIS OF CAPECITABINE IN
ADJUVANT TREATMENT OF STAGE III COLON CANCER 
IN TAIWAN
Hsu TC1, Chen HH2, Chen LT3, Changchien CR4, Liu MC5,
Wang HM6,Yang L7
1Taipei Medical University,Taipei,Taiwan, 2Chang Guang Memorial
Hospital, Kaohsiung Branch, Kaohsiung,Taiwan, 3National Health
Research Institutes,Taipei,Taiwan, 4Chang Guang Memorial Hospital,
Linkou Branch, Linkou,Taiwan, 5Koo Foundation Sun Yat-Sen Cancer
Center,Taipei,Taiwan, 6Taichung Veterans General Hospital,Taichung,
Taiwan, 7Roche Products Ltd,Taipei,Taiwan
OBJECTIVES: Colorectal cancer is the second most commonly
diagnosed cancer and the third cause of cancer-related mortality
in Taiwan. Capecitabine, an oral ﬂuoropyrimidine, is an effec-
tive alternative to intravenous ﬂuorouracil plus leucovorin (5-
FU/LV) in adjuvant treatment of stage III colon cancer. The
